Abstract YO34
Case summary
Background
Alteration in Urinary phosphate levels has been considered to be a paraneoplastic syndrome. This case report sheds light on a rare endocrinological cause of limb weakness.
Case details
A 31 year old female, a known case of pleomorphic leiomyosarcoma post surgery, post adjuvant chemotherapy with recently diagnosed parenchymal and pleural deposits presented with weakness in legs since the past 3 days, abnormal movements involving both the arms since the past 1 day and altered sensorium since the past 2 days. There was no history of symptoms of raised intracranial tension or metastatic spinal cord compression. Examination revealed reduced power in both the upper and lower limbs with downgoing flexors. Further investigation revealed reduced levels of serum phosphate, serum calcium and transaminiitis. Based upon recent reports available with the patient, vitamin D levels were found to be low whereas Intact PTH was found to be normal. A diagnosis of tumor induced osteomalacia versus Pazopanib induced fanconi’s syndrome was considered. She was started on oral phosphate supplements and vitamin D.
Conclusion
Tumor induced osteomalacia needs to be recognized as a reversible causes of quadriparesis in the advanced cancer population with mesenchymal tumours. The diagnosis was made in the Palliative medicine ward in the absence of 24 hour urinary phosphate levels or serum FGF levels.
Laboratory parameters | 24-01-2019 | 25-01-2019 |
Total Calcium | 1.9 | 1.5 |
Serum Urea | 20 | 17 |
Serum Creatinine | 0.5 | 0.4 |
Serum Uric Acid | 3.5 | |
Serum Sodium | 134 | |
Serum Potassium | 3.03 | |
Serum Chloride | 105.8 | |
Serum PTH | 71.90 | |
Serum Vitamin D3 | 12.26 | |
Total leucocyte count | 1070 | 900 |
Serum Haemoglobin | 13.2 | 9.7 |
QTc interval (corrected) | ||
Bazette's | 0.5 | 0.47 |
Frederica's | 0.49 | 0.46 |
Framingham | 0.52 | 0.46 |
Hodges | 0.52 | 0.45 |
Clinical trial identification
Editorial acknowledgement
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract